Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data

Simple item page
dc.contributor.authorAnıl Tombak
dc.contributor.authorFunda Pepedil Tanrıkulu
dc.contributor.authorSalih Sertaç Durusoy
dc.contributor.authorHüseyin Derya Dinçyürek
dc.contributor.authorEmin Kaya
dc.contributor.authorElif Gülsüm Ümit
dc.contributor.authorİrfan Yavaşoğlu
dc.contributor.authorÖzgür Mehtap
dc.contributor.authorBurak Deveci
dc.contributor.authorMehmet Ali Özcan
dc.contributor.authorHatice Terzi
dc.contributor.authorMüfide Okay
dc.contributor.authorNilgün Sayınalp
dc.contributor.authorMehmet Yılmaz
dc.contributor.authorVahap Okan
dc.contributor.authorAlperen Kızıklı
dc.contributor.authorÖmer Özcan
dc.contributor.authorGüven Çetin
dc.contributor.authorSinan Demircioğlu
dc.contributor.authorİsmet Aydoğdu
dc.contributor.authorGüray Saydam
dc.contributor.authorEren Arslan Davulcu
dc.contributor.authorGül İlhan
dc.contributor.authorMehmet Ali Uçar
dc.contributor.authorDerya Selim Batur
dc.contributor.authorRahşan Yıldırım
dc.contributor.authorVildan Özkocamaz
dc.contributor.authorAhmet Kürşad Güneş
dc.contributor.authorBirsen Sahip
dc.contributor.authorŞehmus Ertop
dc.contributor.authorOlga Meltem Akay
dc.contributor.authorAbdülkadir Baştürk
dc.contributor.authorMehmet Hilmi Doğu
dc.contributor.authorAydan AKDENİZ
dc.contributor.authorAli Ünal
dc.contributor.authorAhmet Seyhanlı
dc.contributor.authorEmel Gürkan
dc.contributor.authorDemet Çekdemir
dc.contributor.authorBurhan Ferhanoğlu
dc.date.accessioned2024-07-24T09:11:37Z
dc.date.available2024-07-24T09:11:37Z
dc.date.issued2021
dc.description.abstractObjective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients. Materials and Methods: A total of 136 patients (mean age ± standard deviation: 64.6±10.3 years, 66.9% males) who had received at least one dose of ibrutinib were included in this retrospective multicenter, noninterventional hospital-registry study conducted at 33 centers across Turkey. Data on patient demographics, baseline characteristics, laboratory findings, and leukemia-cell cytogenetics were retrieved. Treatment response, survival outcome including overall survival (OS) and progression-free survival (PFS), and safety data were analyzed. Results: Overall, 36.7% of patients were categorized as Eastern Cooperative Oncology Group (ECOG) class 2-3, while 44.9% were in Rai stage 4. Fluorescence in situ hybridization revealed the presence of del(17p) in 39.8% of the patients. Patients received a median of 2.0 (range: 0-7) lines of pre-ibrutinib therapy. Median duration of therapy was 8.8 months (range: 0.4-58.0 months). The 1-year PFS and OS rates were 82.2% and 84.6%, respectively, while median PFS time was 30.0 (standard error, 95% confidence interval: 5.1, 20.0-40.0) months and median OS time was 37.9 (3.2, 31.5-44.2) months. Treatment response (complete or partial response), PFS time, and OS time were better with 0-2 lines versus 3-7 lines of prior therapy (p<0.001, p=0.001, and p<0.001, respectively), with ECOG class 0-1 versus class 2-3 (p=0.006, p=0.011, and p=0.001, respectively), and with Rai stage 0-2 versus 3-4 (p=0.002, p=0.001, and p=0.002, respectively). No significant difference was noted in treatment response rates or survival outcome with respect to the presence of comorbidity, bulky disease, or del(17p). While 176 adverse events (AEs) were reported in 74 (54.4%) patients, 46 of those 176 AEs were grade 3-4, including pneumonia (n=12), neutropenia (n=11), anemia (n=5), thrombocytopenia (n=5), and fever (n=5). Conclusion: This real-life analysis confirms the favorable efficacy and safety profile of long-term ibrutinib treatment while emphasizing the potential adverse impacts of poorer ECOG performance status, heavy treatment prior to ibrutinib, and advanced Rai stage on patient compliance, treatment response, and survival outcomes.
dc.identifier.DOI-ID10.4274/tjh.galenos.2021.2021.0007
dc.identifier.issn1300-7777
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/23838
dc.language.isoeng
dc.titleEfficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
dc.typeAraştırma Makalesi

Files

Collections

TR-Dizin Koleksiyonu